Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628716 · ClinicalTrials.gov registry record · Phase 2
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03628716 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 43 participants.
The verdict
NCT03628716, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a Phase 2, single-arm, multi-institutional clinical trial designed to study the combination of CV301 with atezolizumab in the first-line treatment of UC not eligible for cisplatin-containing chemotherapy (Cohort 1) and in the second-line treatment of UC previously treated with standard first-line cisplatin-based chemotherapy (Cohort 2).
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL CV301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03628716
The ClinicalTrials.gov registry entry for NCT03628716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03628716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03628716 about?
NCT03628716 is a clinical study titled "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer". This is a Phase 2, single-arm, multi-institutional clinical trial designed to study the combination of CV301 with atezolizumab in the first-line treatment of UC not eligible for cisplatin-containing chemotherapy (Cohort 1) and in the second-line treatment of UC previously treated with standard first...
What is the current status of trial NCT03628716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-09-18. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT03628716?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), CV301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03628716?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.